Q3 26 Results and Key Strategic Milestones

Pacific Edge releases its Investor Update for the three months to the end of December 2025 (Q3 26) today with reports on further strategic achievements to support a reinstatement of Medicare coverage of Cxbladder and the volume of Cxbladder tests processed through its laboratories.

The Investor Update includes:

• A preview of our Medicare Administrative Contractor Novitas’ Contractor Advisory Committee (CAC) meeting to be held on 20 February 12.00pm (NZST)¹, including an overview of what investors should look for from this important meeting. These meetings are generally convened ahead of developing new or substantially revised medical policy as a draft Local Coverage Determination (LCD).
• News that Kaiser Permanente’s Real World evidence study demonstrating Cxbladder Triage’s Clinical Utility has been accepted for publication in Urology Practice and will therefore likely be able to be profiled at the CAC. The study was first previewed at the 2025 American Urological Association annual meeting.
• Progress in the Medicare appeals of Cxbladder Triage tests denied reimbursement since the finalization of the Genetic testing for Oncology LCD: Specific Tests (L39365) that ended coverage of Cxbladder. In January we heard that our first hearing of four cases had been set down for 24 February 2026 just after the CAC meeting.
• Total laboratory throughput (TLT) in Q3 26 fell 13.4% to 5,446 tests from 6,286 in Q2 26. US TLT was down 19.5% to 4,003 tests from 4,971 in Q2 26. APAC volumes rose 9.7% to 1,443 tests from 1,315 in Q2 26 lifted by an increase in commercial test volumes.
• Confirmation that Cxbladder Triage has been endorsed as ‘meeting coverage criteria’ by Avalon Healthcare Systems, a large diagnostic intelligence provider that is used by healthcare payers and providers supporting more than 44 million US lives. This is also important evidence that can be used at the CAC.
• Detail of the farewell to retiring Chair Chris Gallaher, and a profile of our new Chair Simon Flood.

Pacific Edge Chief Executive Dr Peter Meintjes says in the update: “Despite the ongoing throughput challenges that have been amplified by the seasonal holiday slow down, Pacific Edge enters 2026 in the strongest position to establish enduring Medicare coverage policy in a LCD — the strategic focus for more than a decade. If successful, this will establish a materially more certain environment for reimbursement for Cxbladder by Medicare and other providers in the US."

View the Investor Update

¹ 19 February 2026 at 6:00pm (US ET)